Tvardi Therapeutics, Inc. (TVRD) compared with its closest peers (MRKR, BFRI, COCP, NEUP, CELU). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | $23.09M | -1.8 |
| Biofrontera Inc. (BFRI) | $21.91M | -0.7 |
| Cocrystal Pharma, Inc. (COCP) | $21.86M | -1.2 |
| Neuphoria Therapeutics Inc. (NEUP) | $21.35M | 7.9 |
| Celularity Inc. (CELU) | $20.29M | -0.3 |
| Palatin Technologies, Inc. (PTN) | $18.26M | -0.0 |
| Cyclerion Therapeutics, Inc. (CYCN) | $18.21M | -1.1 |
| Tempest Therapeutics, Inc. (TPST) | $17.10M | -0.4 |
| Vyome Holdings, Inc. (HIND) | $16.14M | -0.7 |
| KALA BIO, Inc. (KALA) | $15.24M | — |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
TVRD overview · TVRD earnings · TVRD financials · TVRD KPIs · TVRD investor relations · TVRD ownership · TVRD filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.